| |
 |
 |
 |
 |
 |
 |
 |
 |
|
| HOME
> About Us > Alliances |
|
|
|
As a global leader in genetic medicine, we are involved in the promising
development areas, in line with our corporate philosophy: technologies
and patents from which the development of drugs originates. We have
formed the following strategic alliances to introduce several promising
development areas from universities:
| Daiichi Sankyo
Co., Ltd. |
 |
| Cooperating with us in development of HGF genetic medicine in the fields of peripheral arterial disease (PAD) and Ischemic heart disease (IHD) in Japan.
|
 For
details, see the news release. |
| Vical, Inc. |
|
| AnGes MG and Vical executed a collaborative R&D agreement for Allovectin-7 which is for advanced metastatic melanoma as well as an equity investment agreement. In addition, AnGes MG obtained development and marketing rights of Allovectin-7 in Asia from Vical. |
| For
details, see the news release. |
| BioMarin Pharmaceutical Inc. |
|
| AnGes MG obtained exclusive rights to market and distribute Naglazyme for Mucopolysaccharidosis VI in Japan. |
| For
details, see the news release. |
|
GenomIdea Inc. (Consolidated subsidiary of AnGes MG) |
| Ishihara
Sangyo Kaisha, Ltd. |
|
| Cooperating with us in the manufacture and sale
of reagents with the use of HVJ envelope vectors. Ishihara Sangyo
Kaisha sells high-efficiency transfection kit GenomONE(R). |
| TSD Japan, Inc. |
|
| GenomIdea granted exclusive rights for manufacturing, development and marketing of GEN0101 (HVJ-E) for prostate cancer in Japan to TSD Japan. |
 |
|
 |
| |
The Group is accumulating
various know-how in the field of genetic medicine. If you are
a researcher, with original ideas and agree to the Group's policies,
we welcome your inquiries by all means. |
|
 |
|
 |
|
|
